AIDS Clinical Center, National Center for Global Health and Medicine, 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
Sci Rep. 2013;3:2389. doi: 10.1038/srep02389.
The third variable region (V3) of HIV-1 envelope glycoprotein gp120 plays a key role in determination of viral coreceptor usage (tropism). However, which combinations of mutations in V3 confer a tropism shift is still unclear. A unique pattern of mutations in antiretroviral therapy-naive HIV-1 patient was observed associated with the HIV-1 tropism shift CCR5 to CXCR4. The insertion of arginine at position 11 and the loss of the N-linked glycosylation site were indispensable for acquiring pure CXCR4-tropism, which were confirmed by cell-cell fusion assay and phenotype analysis of recombinant HIV-1 variants. The same pattern of mutations in V3 and the associated tropism shift were identified in two of 53 other patients (3.8%) with CD4(+) cell count <200/mm(3). The combination of arginine insertion and loss of N-linked glycosylation site usually confers CXCR4-tropism. Awareness of this rule will help to confirm the tropism prediction from V3 sequences by conventional rules.
HIV-1 包膜糖蛋白 gp120 的第三可变区(V3)在决定病毒辅助受体的使用(嗜性)方面起着关键作用。然而,V3 中哪些突变组合会导致嗜性转变仍不清楚。在抗逆转录病毒治疗初治的 HIV-1 患者中观察到一种独特的 V3 区突变模式,与 HIV-1 嗜性从 CCR5 转变为 CXCR4 有关。位置 11 的精氨酸插入和 N 连接糖基化位点的缺失是获得纯 CXCR4 嗜性所必需的,这通过细胞融合试验和重组 HIV-1 变体的表型分析得到了证实。在另外 53 名 CD4(+)细胞计数<200/mm(3)的患者中,有 2 名(3.8%)患者的 V3 中也发现了相同模式的突变和相关的嗜性转变。精氨酸插入和 N 连接糖基化位点缺失的组合通常赋予 CXCR4 嗜性。了解这一规则将有助于根据常规规则确认 V3 序列的嗜性预测。